UK-CAB 28 – Meeting report

Late Presenters

30 January 2009
Download report as a pdf file [193 Kb]

Summary

The meeting had 24 attendees, 14 from outside London.

Morning Session

Updates:

  • Roger Peabody is the new BHIVA Representative on the Audit Standards Committee and will be taking over from Gus Cairns when his term runs out. BHIVA is actively looking for a community rep on the Fundraising committee; any interested members should contact the BHIVA chair or the Secretariat.
  • UKCAB is still looking for Steering Group members; the current Steering Group will consider applications from interested members.
  • Robert James announced his resignation from the Steering Group due to work commitments, will continue to attend CAB meetings.
  • A brief demonstration on the use of the forum was done by Michael and urged all members to post and contact Memory if they encounter any problems.

Feedback:

  • Late presenters – BMS/Gilead patient education programme: Michael and Memory had attended a meeting during HIV9 conference in Glasgow. This is a programme designed to train treatment advocates to encourage people to test early and start treatment early. Different issues in Europe include – immigration, social, etc. The aim is to support people to have best treatment options. Question raised is: Does UKCAB want to be part of it, given experiences from some members who had been involved is similar programmes?
  • A webcast from one community session from HIV9 conference was shown and members encouraged to take time to have a look in their own time. Gus presentation at HIV9 will also be available on the UKCAB website shortly.

Immunology session: A rough guide to – Dr Adrian Palfreeman

  • Stem cells: There are two main types of T-cells. T-4 cells, also called CD4, are “helper” cells. They lead the attack against infections. T-8 cells (CD8) are “suppressor” cells that end the immune response. CD8 cells can also be “killer” cells that kill cancer cells and cells infected with a virus.
  • INTERLEUKIN-2 (IL-2) is a protein made by the body. T-helper cells, a kind of white blood cell, produce IL-2 when they are stimulated by an infection. IL-2 makes infection-fighting cells multiply and mature. Patients who use IL-2 have large increases in their CD4 cell counts and given as an intravenous infusion and as twice-daily subcutaneous (below the skin) injections. IL-2 causes irritation where the injections are given and flu-like symptoms.

New MRC HIV Clinical Trials Update – Nick Paton, MRC

  • ESPRIT and SILCAAT: Does IL-2 induced CD4 count increase give clinical benefit?
  • HCQ-01- can it decrease immune activation in HIV infection? 32 patients screened, 10 randomised, sites say it is difficult to identify pts as they do not attend clinic regular. May look for community involvement.
  • PIVOT – monotherapy to reduce long-term toxicity? To look at resistance and toxicity after 5 years. Sub-studies: CNS viral replication, genital secretion VL, body composition, immune activation. To recruit 400 patients.

Afternoon session – Tibotec: 4 presentations on Etravirine, Darunavir and pipeline HIV plus HCV and TB

  • Dr Perry Mohammed: Darunavir – once daily dosing for treatment experienced patients? 200 patients in study on 800mg/day. ODIN study had 600 patients. European monotherapy is in 13 countries with 250 patients
  • Rekha Sinha, MD: Intelence (Etravirine) Update
    • Adverse events: rash, nervous system and psychiatric disorders, hepatic and lab abnormalities
    • Conclusions – generally safe, no severe adverse events due to use of ETR
    • Peter Williams – TMC278 update
    • TMC278 could be best ART – high response rate even with lower dose. Limited no of patients who have shown virological failure. Tolerability v EFV was good; lower rash incidents, lower increases in lipids.
  • MDR TB trial – pre-planned analysis of the stage 1 results after 8wks of treatment
    • No discountiations due to adverse effects
    • Negative sputum identified at least 1 week apart
    • Drug carryover effects were prevented
  • Pipeline and HCV
    • TMC435 – Hep c telaprevir.
    • DDI studies ongoing Tenofovir – no significant interaction
    • RSV353 – respiratory syncitial virus

    Presentations

    Immunology session: A rough guide to

    Dr Adrian Palfreeman

    Immunology session: A rough guide to  – Dr Adrian Palfreeman

    • Stem cells: There are two main types of T-cells. T-4 cells, also called CD4, are “helper” cells. They lead the attack against infections. T-8 cells (CD8) are “suppressor” cells that end the immune response. CD8 cells can also be “killer” cells that kill cancer cells and cells infected with a virus.
    • INTERLEUKIN-2 (IL-2) is a protein made by the body. T-helper cells, a kind of white blood cell, produce IL-2 when they are stimulated by an infection. IL-2 makes infection-fighting cells multiply and mature. Patients who use IL-2 have large increases in their CD4 cell counts and given as an intravenous infusion and as twice-daily subcutaneous (below the skin) injections. IL-2 causes irritation where the injections are given and flu-like symptoms.

    When to Start Therapy? The Patient’s Viewpoint

    Gus Cairns

    When to Start Therapy? The Patient's Viewpoint

    Background – guidelines change. What do we tell patients? Readiness. Swiss HIV Cohort study. Barriers to starting. EACS Algorithm. NAM Study. Quantitative Findings. Qualitative Findings. Themes and Conclusions.

    INTELENCE (Etravirine) UPDATE

    Rekha Sinha, MD

    INTELENCE (Etravirine) UPDATE

    Etravirine (ETR) Safety and Tolerability – Pooled Data from Phase III Trials – Short-term safety in Pediatric Population Planned Trials with Etravirine Etravirine Resistance

    TMC278 Update

    Peter Williams Tibotec

    TMC 278 Update slide set

    C204 data - ECHO and THRIVE – Phase III studies - New TMC278 formulations

    TMC207 Update

    Karel de Beule

    TMC207 Update

    Interim analysis of a double-blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis

    Pipeline & HCV

    Tibotec

    Pipeline and HCV drugs

    TMC435, RSV353 , DDI studies ongoing. Tenofovir: no significant interaction Coinfection study: pilot study will start this year

    Overview

    Overview

    Update on Darunavir: Perry Mohammed. Update on Etravirine: Rekha Sinha. Update on TMC278: Peter Williams. Update on TMC207: Karel De Beule. HCV pipeline: Daniel de Schryver.

    Edit
    Published: January 30, 2009
    Last edited: December 19, 2010